HVR Cardio has secured a €10.7 million Series B funding round. The Finnish Innovestor Life Science Fund and Tesi spearheaded the round, which ranks among the highest ever raised by a Finnish medtech company.
HVR Cardio, a clinical-stage company specialising in medical technology, focuses on developing Structural Heart cardiovascular products designed for transcatheter mitral valve repair.